GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Other Long Term Assets

Pharming Group (XAMS:PHARM) Other Long Term Assets : €30.7 Mil (As of Dec. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Pharming Group Other Long Term Assets?

Pharming Group's other long-term assets for the quarter that ended in Dec. 2024 was €30.7 Mil.

Pharming Group's quarterly other long-term assets declined from Jun. 2024 (€37.8 Mil) to Sep. 2024 (€34.6 Mil) but then stayed the same from Sep. 2024 (€34.6 Mil) to Dec. 2024 (€30.7 Mil).

Pharming Group's annual other long-term assets increased from Dec. 2022 (€22.9 Mil) to Dec. 2023 (€28.8 Mil) and increased from Dec. 2023 (€28.8 Mil) to Dec. 2024 (€30.7 Mil).

Pharming Group Other Long Term Assets Historical Data

The historical data trend for Pharming Group's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Other Long Term Assets Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.62 19.67 22.94 28.78 30.69

Pharming Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.78 34.29 37.75 34.59 30.69

Pharming Group Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Pharming Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Other Long Term Assets
Comparable Companies
XAMS:VVY XAMS:GLPG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270 SMMT RPRX XKRX:196170 OCSE:GMAB INSM BMRN HKSE:02269 SHSE:603392
Traded in Other Exchanges
PHAR:USA PHGUF:USA 0QCO:UK PHG:Germany PHGN:Germany
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Website
https://www.pharming.com
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines